IL288957A - Pyrazolopyrimidine sulfone inhibitors of jak kinases and their uses - Google Patents
Pyrazolopyrimidine sulfone inhibitors of jak kinases and their usesInfo
- Publication number
- IL288957A IL288957A IL288957A IL28895721A IL288957A IL 288957 A IL288957 A IL 288957A IL 288957 A IL288957 A IL 288957A IL 28895721 A IL28895721 A IL 28895721A IL 288957 A IL288957 A IL 288957A
- Authority
- IL
- Israel
- Prior art keywords
- pyrazolopyrimidine
- jak kinases
- sulfone inhibitors
- sulfone
- inhibitors
- Prior art date
Links
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- -1 Pyrazolopyrimidine sulfone Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019091712 | 2019-06-18 | ||
| US202063035381P | 2020-06-05 | 2020-06-05 | |
| PCT/US2020/037853 WO2020257145A1 (en) | 2019-06-18 | 2020-06-16 | Pyrazolopyrimidine sulfone inhibitors of jak kinases and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL288957A true IL288957A (en) | 2022-02-01 |
Family
ID=71575774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL288957A IL288957A (en) | 2019-06-18 | 2021-12-13 | Pyrazolopyrimidine sulfone inhibitors of jak kinases and their uses |
Country Status (18)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114026096B (zh) | 2019-06-18 | 2025-02-07 | 豪夫迈·罗氏有限公司 | 四唑取代的吡唑并嘧啶类jak激酶抑制剂及其用途 |
| KR102767443B1 (ko) * | 2022-04-14 | 2025-02-12 | 한국화학연구원 | 퀴녹살린 카르복스아마이드 유도체 및 이를 유효성분으로 포함하는 교모세포종의 예방 또는 치료용 약학적 조성물 |
| EP4522598A1 (en) | 2022-05-11 | 2025-03-19 | PI Industries Ltd. | Bicyclic compounds and their use as pest control agents |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| JPH11508583A (ja) | 1995-07-06 | 1999-07-27 | ゼネカ・リミテッド | ペプチド系のフィブロネクチン阻害薬 |
| US6248713B1 (en) | 1995-07-11 | 2001-06-19 | Biogen, Inc. | Cell adhesion inhibitors |
| YU25500A (sh) | 1999-05-11 | 2003-08-29 | Pfizer Products Inc. | Postupak za sintezu analoga nukleozida |
| GB0028383D0 (en) | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
| EP1241176A1 (en) | 2001-03-16 | 2002-09-18 | Pfizer Products Inc. | Purine derivatives for the treatment of ischemia |
| AU2002361992A1 (en) | 2001-12-20 | 2003-07-09 | Bayer Aktiengesellschaft | 1,4-dihydro-1,4-diphenylpyridine derivatives |
| SE0302487D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| GB0502258D0 (en) | 2005-02-03 | 2005-03-09 | Argenta Discovery Ltd | Compounds and their use |
| CN101616921A (zh) * | 2007-01-30 | 2009-12-30 | 比奥根艾迪克Ma公司 | 1-H-吡唑并(3,4b)嘧啶衍生物及其作为有丝分裂激酶调节剂的用途 |
| AU2008211172A1 (en) * | 2007-01-30 | 2008-08-07 | Biogen Idec Ma Inc. | 1-H-pyrazolo(3,4B)pyrimidine derivatives and their use as modulators of mitotic kinases |
| AU2009259853A1 (en) | 2008-06-20 | 2009-12-23 | Genentech, Inc. | Triazolopyridine JAK inhibitor compounds and methods |
| BRPI0914404A2 (pt) | 2008-10-31 | 2019-03-06 | Genentech Inc | "compostos, composição farmacêutica e método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak quinase em um paciente" |
| UA110324C2 (en) * | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
| US8575336B2 (en) | 2011-07-27 | 2013-11-05 | Pfizer Limited | Indazoles |
| HUE047441T2 (hu) | 2012-11-09 | 2020-04-28 | Medicines For Malaria Venture Mmv | Heteroaril-származékok és alkamazásaik |
| HRP20210935T1 (hr) | 2014-05-23 | 2021-08-06 | F. Hoffmann - La Roche Ag | Spojevi 5-kloro-2-difluorometoksifenil pirazolopirimidina koji predstavljaju inhibitore jak |
| TW201720828A (zh) | 2015-11-23 | 2017-06-16 | 赫孚孟拉羅股份公司 | 治療性化合物及組合物以及其使用方法 |
| WO2017140825A1 (en) | 2016-02-18 | 2017-08-24 | F. Hoffmann-La Roche Ag | Therapeutic compounds, compositions and methods of use thereof |
| MX2019007339A (es) | 2016-12-29 | 2019-09-06 | Hoffmann La Roche | Compuestos de pirazolopirimidina y metodos de uso de los mismos. |
| JP2020510061A (ja) | 2017-03-14 | 2020-04-02 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ピラゾロクロロフェニル化合物、組成物及びその使用方法 |
| WO2018215390A1 (en) * | 2017-05-22 | 2018-11-29 | F. Hoffmann-La Roche Ag | Therapeutic compounds and compositions, and methods of use thereof |
| JP7256757B2 (ja) | 2017-05-22 | 2023-04-12 | エフ. ホフマン-ラ ロシュ アーゲー | 処置用化合物及び組成物、並びにその使用方法 |
| WO2019139714A1 (en) * | 2018-01-15 | 2019-07-18 | Genentech, Inc. | Pyrazolopyrimidine compounds as jak inhibitors |
| CA3127701C (en) * | 2019-01-25 | 2023-08-15 | Beijing Scitech-Mq Pharmaceuticals Limited | Acylamino bridged heterocyclic compound, and composition and application thereof |
| CN114026096B (zh) | 2019-06-18 | 2025-02-07 | 豪夫迈·罗氏有限公司 | 四唑取代的吡唑并嘧啶类jak激酶抑制剂及其用途 |
| EP3986899A1 (en) | 2019-06-18 | 2022-04-27 | F. Hoffmann-La Roche AG | Pyrazolopyrimidine aryl ether inhibitors of jak kinases and uses thereof |
-
2020
- 2020-06-16 JP JP2021574283A patent/JP7657740B2/ja active Active
- 2020-06-16 CR CR20210661A patent/CR20210661A/es unknown
- 2020-06-16 EP EP20739492.5A patent/EP3986901A1/en active Pending
- 2020-06-16 TW TW109120272A patent/TW202115068A/zh unknown
- 2020-06-16 WO PCT/US2020/037853 patent/WO2020257145A1/en not_active Ceased
- 2020-06-16 US US16/902,499 patent/US11453671B2/en active Active
- 2020-06-16 KR KR1020227000044A patent/KR20220024405A/ko not_active Ceased
- 2020-06-16 PH PH1/2021/552998A patent/PH12021552998A1/en unknown
- 2020-06-16 BR BR112021025618A patent/BR112021025618A2/pt not_active Application Discontinuation
- 2020-06-16 PE PE2021002182A patent/PE20220577A1/es unknown
- 2020-06-16 AU AU2020297415A patent/AU2020297415A1/en not_active Abandoned
- 2020-06-16 CN CN202080044750.2A patent/CN114008051B/zh active Active
- 2020-06-16 MX MX2021015319A patent/MX2021015319A/es unknown
- 2020-06-16 CA CA3140024A patent/CA3140024A1/en active Pending
- 2020-06-16 MA MA056518A patent/MA56518A/fr unknown
-
2021
- 2021-12-13 IL IL288957A patent/IL288957A/en unknown
- 2021-12-14 CL CL2021003341A patent/CL2021003341A1/es unknown
-
2022
- 2022-01-12 CO CONC2022/0000118A patent/CO2022000118A2/es unknown
- 2022-08-24 US US17/821,851 patent/US20230016791A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021015319A (es) | 2022-04-07 |
| CR20210661A (es) | 2022-02-11 |
| CN114008051B (zh) | 2024-08-13 |
| PE20220577A1 (es) | 2022-04-20 |
| TW202115068A (zh) | 2021-04-16 |
| US20230016791A1 (en) | 2023-01-19 |
| US20200399275A1 (en) | 2020-12-24 |
| WO2020257145A1 (en) | 2020-12-24 |
| KR20220024405A (ko) | 2022-03-03 |
| PH12021552998A1 (en) | 2023-08-14 |
| JP7657740B2 (ja) | 2025-04-07 |
| US11453671B2 (en) | 2022-09-27 |
| CL2021003341A1 (es) | 2022-07-22 |
| MA56518A (fr) | 2022-04-27 |
| EP3986901A1 (en) | 2022-04-27 |
| CO2022000118A2 (es) | 2022-01-28 |
| JP2022537964A (ja) | 2022-08-31 |
| BR112021025618A2 (pt) | 2022-02-01 |
| CA3140024A1 (en) | 2020-12-24 |
| AU2020297415A1 (en) | 2022-01-06 |
| CN114008051A (zh) | 2022-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3065954T3 (en) | Fgfr inhibitors and methods of use thereof | |
| SG11202106861UA (en) | Lash extensions and methods of manufacture and use thereof | |
| SG11202002947TA (en) | Substituted pyrrolopyrimidine jak inhibitors and methods of making and using the same | |
| ZA202000561B (en) | Pyrazolo and triazolo bicyclic compounds as jak kinase inhibitors | |
| IL287973A (en) | acss2 inhibitors and methods of their use | |
| EP3962484A4 (en) | RAF KINASE INHIBITORS | |
| SG11202109568TA (en) | Pyridazinones and methods of use thereof | |
| IL279475A (en) | Actonucleotidase inhibitors and methods of using them | |
| IL285117A (en) | Methods for characterizing properties related to condensation of compounds and their uses | |
| IL285927A (en) | Combinations of rad51 and parp inhibitors | |
| EP3986894A4 (en) | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | |
| IL267671A (en) | Pyrazolopyrimidine compounds and methods of their use | |
| IL286697A (en) | Neurogulin-4 compounds and methods of use | |
| IL279314A (en) | Small molecule inhibitors of the JAK family of kinases | |
| EP3959197A4 (en) | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | |
| GB202003778D0 (en) | Use of lactoferrin | |
| IL291146A (en) | Treatment of hidradenitis with jak inhibitors | |
| GB2589398B (en) | Compounds and methods of use | |
| EP3946606C0 (en) | BICYCLIC JAK INHIBITORS AND THEIR USES | |
| MA56518A (fr) | Inhibiteurs de sulfone pyrazolopyrimidine de jak kinases et leurs utilisations | |
| ZA202108165B (en) | Application of kdm5a gene and atrx gene | |
| GB201809371D0 (en) | Gimbals and methods of manufacturing gimbals | |
| EP4011880A4 (en) | JAK KINASE INHIBITOR AND USE THEREOF | |
| EP4444309A4 (en) | PYRIMIDINS AND THEIR METHODS OF USE | |
| HK40070274A (en) | Inhibitors of raf kinases |